[Thiotriazoline in the Treatment of Stable Angina IIIII Functional Class].

Abstract

Trimetazidine is a metabolic agent of proven efficacy in improving myocardial ischemia and angina. A comparative international multicenter randomized trial, assessed anti-anginal anti ischemic efficacy and safety of Trimetazidine (60 mg/d) and Thiotriazoline (600 mg/d) in symptomatic patients with chronic ischemic heart disease receiving the first line therapy. The study assessed the efficacy of the two drugs on total exercise duration, time to 1-mm ST segment depression, the number of angina attacks and nitroglycerin tablets consumed amount. Both drugs have demonstrated clinical efficacy equal for all primary and secondary endpoints.

• Authors: D V Kadin, B A Chumak, A E Filippov, S B Shustov
• Journal: Kardiologiia (Kardiologiia) Vol. 55 Issue 8 Pg. 26-29 (Aug 2015) ISSN: 0022-9040 [Print] Russia (Federation)
• PMID: 28294915 (Publication Type: English Abstract, Journal Article)